CTMX
CytomX Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.71
+0.82%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 18.3M | 76.2M | 138.1M | 101.2M | 53.2M |
| Cost of Revenue | 251.0K | — | — | — | — |
| Gross Profit | 18.1M | 76.2M | 138.1M | 101.2M | 53.2M |
| Operating Expenses | |||||
| R&D Expense | 73.4M | 68.7M | 83.4M | 77.7M | 111.6M |
| SG&A Expense | 32.1M | 29.8M | 29.7M | 30.0M | 42.8M |
| General & Admin Expense | 32.1M | 29.8M | 29.7M | 30.0M | 42.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (251.0K) | — | — | — | — |
| Total Operating Expenses | 105.2M | 98.6M | 113.1M | 107.7M | 154.5M |
| Cost and Expenses | 105.5M | 98.6M | 113.1M | 107.7M | 154.5M |
| Operating Income (EBIT) | (87.2M) | (22.4M) | 25.0M | (6.5M) | (101.3M) |
| Non-Operating | |||||
| Interest Income | 7.7M | 5.2M | 7.1M | 9.8M | 1.7M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 7.7M | 5.2M | 7.1M | 9.8M | 1.7M |
| Other Non-Op Income/Expense | 7.7M | 5.2M | 7.1M | 9.8M | 2.0M |
| Non-Operating Income (excl Interest) | (7.7M) | (5.2M) | (7.1M) | (9.8M) | (2.0M) |
| EBT (Pre-Tax Income) | (79.4M) | (17.1M) | 32.1M | 3.3M | (99.3M) |
| Income Tax Expense | 231.0K | 238.0K | 224.0K | 3.9M | — |
| Bottom Line | |||||
| Net Income | (79.7M) | (17.4M) | 31.9M | (569.0K) | (99.3M) |
| Earnings from Cont. Ops | (79.7M) | (17.4M) | 31.9M | (569.0K) | (99.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (79.7M) | (17.4M) | 31.9M | (569.0K) | (99.3M) |
| Per Share | |||||
| Basic EPS | ($0.45) | ($0.15) | $0.38 | ($0.01) | ($1.48) |
| Diluted EPS | ($0.45) | ($0.15) | $0.38 | ($0.01) | ($1.48) |
| Revenue Per Share | $0.08 | $0.55 | $1.64 | $1.37 | $0.81 |
| Shares | |||||
| Basic Shares Outstanding | 218.9M | 137.9M | 84.4M | 73.8M | 65.7M |
| Diluted Shares Outstanding | 218.9M | 137.9M | 84.7M | 73.8M | 65.7M |
| Profitability Metrics | |||||
| EBITDA | (78.2M) | (15.8M) | 33.9M | 5.5M | (96.9M) |
| D&A | 1.2M | 1.4M | 1.8M | 2.2M | 2.4M |
| EBIT | (79.4M) | (17.1M) | 32.1M | 3.3M | (99.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026